This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Luoxis Awarded Health Canada Approval For RedoxSYS™ Diagnostic System

Stocks in this article: AMPE

GREENWOOD VILLAGE, Colo., April 22, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc., (NYSE MKT: AMPE) today announced that its subsidiary Luoxis, an in vitro diagnostics company, has obtained Health Canada Class II Medical Device approval for its RedoxSYS™ Diagnostic System, the company's blood-based platform for assessing the level of oxidative stress in the body.

Luoxis Diagnostics Logo.

The RedoxSYS System received CE Marking in the European Union (EU) earlier this month, where Luoxis has begun collaborating with leading hospitals and research centers.  With Health Canada approval now in place, the company will begin building partnerships with prominent hospitals and academic centers to develop the market in Canada.  In parallel with the company's development of the clinical market, Luoxis is working with pharmaceutical and biotechnology companies on a range of pharmaceutical pre-clinical and clinical programs.  Luoxis has recently signed a long-term research agreement with a global, US-based pharmaceutical company.      

Josh Disbrow, Chief Executive Officer of Luoxis, stated, "Regulatory approval from Health Canada provides additional validation for our RedoxSYS System, and it demonstrates the company's commitment to move the RedoxSYS System toward commercialization in key markets around the world.  We are making substantial progress on the company's three key objectives – establishing clinical validation and utility of the RedoxSYS System, gaining regulatory clearance in key markets around the world, and introducing this novel platform to pharmaceutical companies for use in drug development.  By achieving these objectives we expect to enable broad clinical and scientific adoption worldwide for the RedoxSYS System."

With regulatory clearances in both Europe and Canada, the company is now engaged in discussions with potential commercialization partners. Luoxis is evaluating various strategic options to maximize the commercial success of the RedoxSYS System, inclusive of both global and regional distribution arrangements. 

About the RedoxSYS Diagnostic SystemThe RedoxSYS Diagnostic System is a first-in-class clinical diagnostic platform that measures oxidation-reduction potential (ORP) in the body, a homeostatic measurement of oxidative stress that changes in response to traumatic injury or illness.  The result of nearly two decades of clinical, scientific and technical R&D, the RedoxSYS System is able to provide the only complete assessment of a patient's oxidative status, which has broad diagnostic application across multiple disease areas where oxidative stress is implicated.  Luoxis is currently developing RedoxSYS as a simple, rapid blood test for use in the critical care setting, where its ability to provide an objective measurement of patient illness and predict potential complications may enable physicians to improve resource allocation and align higher levels of care with the most critically injured and ill patients, leading to improved outcomes and optimal workflows.

About LuoxisLuoxis is an in vitro diagnostics company focused on developing and commercializing its proprietary, CE Marked RedoxSYS Diagnostic System.  The company is currently developing RedoxSYS to address the $4+ billion critical care market, where it has the potential to provide hospitals with a single, rapid solution with unmatched diagnostic/prognostic value for conditions with significant medical need, and for which few diagnostic biomarkers exist.  Luoxis is conducting initial market development for RedoxSYS in select European territories in order to validate and quantify the clinical value of RedoxSYS for monitoring injury severity and patient oxidative stress following traumatic brain injury, multi-trauma injury, and other critical illnesses.  Luoxis is also pursuing U.S. regulatory clearance for RedoxSYS, based on completed and ongoing clinical studies in multiple critical care conditions in the United States, including TBI, multi-trauma injury, stroke, sepsis, ventilator-associated pneumonia (VAP), and other life-threatening conditions.  Luoxis has research collaborations in place with leading centers around the world.  Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.  For more information, visit

About Ampio PharmaceuticalsAmpio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

RedoxSYS and Luoxis are trademarks of Luoxis Diagnostics, Inc.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs